Low-dose radiation plus immunotherapy for metastatic nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have newly diagnosed nasopharyngeal cancer that has spread to other parts of the body (metastatic), with no more than 10 spots of spread.
- You are not able to receive standard platinum-based chemotherapy, or you have decided not to after discussing it with your doctor.
- Your cancer cells have a protein called PD-L1 (a marker that helps the immunotherapy work), with a CPS score of 1 or higher.
- You are physically able to perform daily activities (ECOG performance status 0-2).
- You have adequate organ function, such as healthy bone marrow, liver, and kidneys, and your heart pumps normally (LVEF of 45% or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether giving an immunotherapy drug (sintilimab) combined with a pill chemotherapy (capecitabine) after standard treatment can help prevent nasopharyngeal cancer from coming back in people with high-risk stages. You must have already completed standard chemo-immunotherapy and radiation.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiation works better than chemoradiation alone for people with a specific type of advanced nasopharyngeal cancer. It aims to shrink tumors before surgery and prevent cancer from coming back.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This Phase 2 trial tests adding a PD-1 “immunotherapy” medicine (a type of cancer-fighting antibody) along with stereotactic body radiotherapy (very focused radiation) to treat nasopharyngeal cancer that has spread to only a few places. It may help shrink remaining visible spots after initial local radiation and see whether this “consolidation” approach improves control of the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.